Shernan Holtan: A positive but negative GVHD prophylaxis story with JAK2i

Shernan Holtan, Chief of the Blood and Marrow Transplant Program at Roswell Park, shared on LinkedIn about recent paper by Joseph A Pidala et al., titled “JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results” published on Blood.

Authors: Joseph A Pidala, Shernan G Holtan, Kelly Walton, Jongphil Kim, Biwei Cao, Hany Elmariah, Asmita Mishra, Nelli Bejanyan, Taiga Nishihori, Farhad Khimani, Lia E Perez, Rawan G Faramand, Marco L. Davila, Shannon McSain, Jordan Pleskow, Jeffrey Baron, Claudio Anasetti, Carlos M Moran Segura, Daniel J Weisdorf, Bruce R Blazar, Jeffrey S. Miller, Veronika Bachanova, Najla El Jurdi, Brian C Betts

“A positive but negative GVHD prophylaxis story with JAK2i.

Pacritinib reduced STAT3 in CD4 T cells (met primary endpoint!) and reduced Th1/Th17 cells in the blood at day +21.

However, this biological efficacy did not translate to patient benefit. Clinically, JAK2i did not prevent GVHD.

Humbling.”

Source: Shernan Holtan/LinkedIn